Takeda Pharmaceutical Company Limited (BST:TKDA)
Germany · Delayed Price · Currency is EUR | Market Cap | 44.90B +11.4% |
| Revenue (ttm) | 24.58B -1.7% |
| Net Income | 1.05B +77.7% |
| EPS | 0.65 +78.0% |
| Shares Out | n/a |
| PE Ratio | 42.93 |
| Forward PE | n/a |
| Dividend | 0.23 (1.65%) |
| Ex-Dividend Date | Sep 30, 2025 |
| Volume | n/a |
| Average Volume | 185 |
| Open | 14.00 |
| Previous Close | 14.20 |
| Day's Range | 14.00 - 14.40 |
| 52-Week Range | 11.60 - 16.20 |
| Beta | n/a |
| RSI | 43.52 |
| Earnings Date | May 13, 2026 |
About BST:TKDA
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livte... [Read more]
Financial Performance
In fiscal year 2026, BST:TKDA's revenue was 4.51 trillion, a decrease of -1.66% compared to the previous year's 4.58 trillion. Earnings were 191.76 billion, an increase of 77.68%.
Financial numbers in JPY Financial StatementsNews
Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results
(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) said Tuesday a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the AMITIZA or lubiprostone ...
Takeda Pharmaceutical (TAK) Found Guilty in Generic Drug Delay Conspiracy
Takeda Pharmaceutical (TAK) Found Guilty in Generic Drug Delay Conspiracy
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.
Jury finds Takeda caused about $885M in damages over generic delay, Reuters says
A U.S. jury on Monday determined that Takeda (TAK) Pharmaceutical caused pharmacies, insurers, retailers, and others to sustain roughly $885M in damages by postponing the release of a generic version…
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
A U.S. jury on Monday found that Takeda Pharmaceutical caused pharmacies, insurers, retailers and others to sustain about $885 million in damages delaying the release of a generic version o...
Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says
A federal jury in the U.S. District Court for the District of Massachusetts found Takeda (TAK) Pharmaceuticals liable for violating antitrust law by delaying the generic version of its branded…
Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says
14:25 EDT Takeda (TAK) ordered by pay hundreds of millions in antitrust case, Bloomberg says
Full Year 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
Full Year 2026 Takeda Pharmaceutical Co Ltd Earnings Presentation Transcript
Takeda Pharmaceutical Q4 Earnings Call Highlights
Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around thr...
Justice Department announces $13.67M civil settlement with Takeda
The Department of Justice said Takeda (TAK) Pharmaceuticals has agreed to pay $13.67M to resolve allegations that it “knowingly caused the submission of false claims to Medicare and other federal…
Takeda Pharmaceutical (TAK) Announces Global Restructuring with Job Cuts
Takeda Pharmaceutical (TAK) Announces Global Restructuring with Job Cuts
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with a restructuring to centralize corporate functions and reduce costs.
Takeda (TAK) Preserved FY2025 Margins, but FY2026 Now Depends on the Launch Pipeline
Takeda Pharmaceutical (TAK) delivered what investors needed from fiscal 2025: enough cost control and cash generation to offset a tougher... The post Takeda (TAK) Preserved FY2025 Margins, but FY2026 ...
Takeda Pharmaceutical Company Earnings Call Transcript: Q4 2026
FY 2025 saw resilient financials despite VYVANSE LOE, with core revenue at JPY 4.5T and strong cash flow. Three late-stage assets are set for launch, supporting a new growth phase, while a transformation program aims to boost efficiency and margins.
Takeda Pharmaceutical Company Slides: Q4 2026
Takeda Pharmaceutical Company has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Takeda Pharmaceutical Company Quarterly report: Q4 2026
Takeda Pharmaceutical Company has published its Q4 2026 quarterly earnings report on May 13, 2026.
Takeda Pharmaceutical (TAK) Reports FY Non-GAAP EPS of ¥517.00 Amid Revenue Decline
Takeda Pharmaceutical (TAK) Reports FY Non-GAAP EPS of ¥517.00 Amid Revenue Decline
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with i...
Takeda Pharmaceutical Announces Positive Data From TAK-881 Trial
(RTTNews) - Monday, Takeda Pharmaceutical Company Limited (TAK) announced positive topline data from TAK-881-3001, a pivotal Phase 2/3 clinical trial evaluating TAK-881 in patients with Primary Immuno...
Takeda announces TAK-881-3001 trial in PID met primary endpoint
Takeda (TAK) announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease, met its primary endpoint, which demonstrated pharmacokinetic comparabili...
Takeda's immune disease drug meets main goal of mid-to-late stage trial
Takeda Pharmaceutical said its experimental drug for primary immunodeficiency disease, a rare condition that weakens the immune system, has met the main goal of a mid- to late-stage cli...
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.
Takeda Pharmaceutical Enters Oversold Territory (TAK)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
The polycythemia vera market is set for expansion by 2036, as new entrants such as Protagonist Therapeutics and Takeda Pharmaceuticals (rusfertide), Merck (bomedemstat), Italfarmaco (givinostat), Ioni...
Takeda upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Takeda (TAK) to Outperform from Market Perform with a price target of 6,900 yen, up from 5,100 yen, citing “bold” cost cuts and multiple upcoming de-risking events for